The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations.
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - TYME; Xencor; Zymeworks
Research Funding - ArQule (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; Orion; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Gopa Iyer
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Olaf Witt
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Research & Development; Novartis; Roche
 
Toshihiko Doi
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Boehringer Ingelheim; Daiichi Sankyo; MSD; Novartis; Otsuka; Rakuten Medical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Christine Lu-Emerson
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Janssen
 
Darren R. Hargrave
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Janssen; Novartis; PureTech; Roche/Genentech
Research Funding - AstraZeneca
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis; Roche/Genentech
Other Relationship - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Epizyme; Janssen; Novartis
 
Javier García-Corbacho
Consulting or Advisory Role - SOLTI
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Shonda Marie Little
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Qi Xia
Employment - SDS Oncology
 
Ademi E. Santiago-Walker
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Christopher Moy
Employment - Janssen Research & Development
 
Constance Hammond
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Hussein Sweiti
Employment - Janssen Research & Development
 
Martin H. Schuler
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MorphoSys; Novartis; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)